BGMedicine, a life sciences company focused on the development and commercialization of molecular diagnostics based on biomarkers, will now offer their 4.5 million shares at a range of $8.00 to $10.00 as opposed to the previously planned range of $14 to $16. Cowen and Company is the sole book runner on the deal.
